Organ Transplant Immunosuppressant Drugs Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.
Organ Transplant Immunosuppressant Drugs Market
Organ Transplant Immunosuppressant Drugs Market Drivers and Restrains:
Successful transplantations have been performed for the kidneys, liver, heart, lungs, pancreas, thymus, and intestine. Kidney transplants are the most common as compared to liver and heart transplants. Organ transplant immunosuppressant drugs are the class of drugs which are managed to reduce the risks of organ rejection after transplantation. When a person experiences any transplantation, the body recognizes the transplant as a foreign tissue and attacks it, resulting in rejection. These drugs dilute the immune system, hence fuel demand for advanced immunosuppressant drugs to prevent organ rejection post-transplantation. These transplantations help in the survival of many patients as well as enhance the quality of life.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.
The organ transplant immunosuppressant drugs market has driven by such factors are technological advancements in organ transplants, tissue engineering and increasing incidences of chronic diseases leading to organ failure and disabilities. According to the U.S. Department of Health and Human Services, Health Resources & Services Administration, XX transplants were executed in 2018 and more than XX people required transplants as of next year. However, high cost of procedure and inadequate, lack of donor organs and the advent of stem cells are the major restraining factor of the market growth at the global level. Novel medication options and the increase in the use of tissue engineering for the generation of implants are provided growth opportunity in the organ transplant immunosuppressant drugs market.
Organ Transplant Immunosuppressant Drugs Market Segmentation Analysis:
Based on the transplant type, the organ transplant immunosuppressant drugs market has been segmented into Kidney, Liver, Heart, Lung, and Pancreas. The kidney transplant segment held the largest market share in 2018 due to increasing demand and relatively better organ availability than other transplants. Kidney transplantation has developed as the most preferred treatment method for end-stage renal diseases and it has proven more cost-effective than prolonged periods of dialysis. The liver and heart transplants segments are also expected to grow at the highest CAGR of XX% in the near future due to the current rate of adoption and future growth prospects. Heart transplantation is currently regarded as the gold standard of treatment as it has revolutionized end-stage heart failure therapy. The liver transplantation has become a life-saving technique for patients with chronic end stage liver disease and selected patients with acute liver failure (ALF) and alcoholic liver disease (ALD).
Based on the distribution channel, the organ transplant immunosuppressant drugs market has been segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. In terms of revenue the hospital pharmacies and retail pharmacies segments held the dominant market share in 2018, because of hospital pharmacies offer easy and rapid access, while retail pharmacies usually have sufficient products in stock. Online pharmacies segments are expected to grow at the largest CAGR of XX% during the upcoming period owing to the growing popularity of eCommerce channels for obtaining prescribed immunosuppressant drugs. Online pharmacies offer a wide range of options and in-depth information about these drugs, due to which an increasing consumer preference for online channels.
Organ Transplant Immunosuppressant Drugs Market Regional Analysis:
Geographically, the organ transplant immunosuppressant drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe held the largest market share of XX% in 2018 due to the higher number of organ transplantations conducted in the region, the recent improvements in surgical techniques, technology, and immunosuppressant drug discovery.
The high healthcare expenditure, established R&D infrastructure, favorable healthcare reimbursement policies and huge demand for organ transplants, these factors are driving the regional market growth. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period due to an increasing revenue generation from calcineurin inhibitors and mTOR inhibitors in this region. Encouraging initiatives pertaining to the increasing investments by the governments and manufacturers in the healthcare sector and sufficiently new opportunities are the key factors impelling the market growth in this region.
A report covers the recent development in market for the organ transplant immunosuppressant drugs market like, In November 2018, Veloxis Pharmaceuticals in association with Temple University, began a phase IV clinical trial of tacrolimus for use in kidney transplant recipients and its completion was expected by August 2019.
Organ Transplant Immunosuppressant Drugs Market Competitive landscape
Major Key players operating in this market are Astellas Pharma Inc, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc. and Novartis AG. Manufacturers in the organ transplant immunosuppressant drugs are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.
The objective of the report is to present comprehensive analysis of organ transplant immunosuppressant drugs market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.
The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding organ transplant immunosuppressant drugs market dynamics, structure by analyzing the market segments, and project the organ transplant immunosuppressant drugs market size. Clear representation of competitive analysis of key players by drug class, price, financial position, product portfolio, growth strategies, and regional presence in the organ transplant immunosuppressant drugs market make the report investor’s guide.
For More Information Visit @:
Scope of the Organ Transplant Immunosuppressant Drugs Market:
Organ Transplant Immunosuppressant Drugs Market, by Drug Class
• Calcineurin Inhibitors
• Antiproliferative Agents
• mTOR Inhibitor
• Steroids
• Antibodies
Organ Transplant Immunosuppressant Drugs Market, by Transplant Type
• Kidney
• Liver
• Heart
• Lung
• Pancreas
Organ Transplant Immunosuppressant Drugs Market, by Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Organ Transplant Immunosuppressant Drugs Market, by Region
• Asia Pacific
• North America
• Europe
• Latin America
• Middle East Africa
Organ Transplant Immunosuppressant Drugs Market, Major Players
• Astellas Pharma Inc,
• Genzyme Corporation
• Accord Healthcare Ltd.
• Watson Pharmaceuticals, Inc.
• Novartis AG
• Mylan Laboratories, Inc.
• GlaxoSmithKline plc
• Hoffman La Roche.
• Sanofi
• F. Hoffmann-La Roche Ltd.
• Veloxis Pharmaceuticals A/S
• Bristol-Myers Squibb Company.
• Pfizer
• Terumo Corporation
• Transmed
• Transonic
• Preservation Solutions Inc.
• Organ Recovery Systems
• XVIVO Perfusion
This Report Is Submitted By : Maximize Market Research Company
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Contact info:
Name: Lumawant Godage
Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.
Email: sales@maximizemarketresearch.com
Address: Pune, Maharashtra 411051, India.
Contact: +919607195908
No comments:
Post a Comment